Antiphospholipid antibodies and their clinical importance

Authors: Z. Fojtík
Authors‘ workplace: Interní hematoonkologická klinika, FN Brno
Published in: Čes. Revmatol., , 2004, No. 3, p. 103-109.


Antiphospholipid antibodies (APLA) represent a heterogenous group of antibodieswhichmayaffectdifferent coagulation cascade pathways by analogy with involvement of phospholipid surfaces invarious steps of blood coagulation. The result of this process leads usually to some degree ofthrombophilia. The most frequently detected APLA are represented by lupus anticoagulant (LA)and anticardiolipin antibodies (aCL). Protein cofactors of antigen determinantswhich are involvedinAPLAgeneration are β2-GPI, prothrombin, proteinC, protein S, annexinV, high andlow molecularmass kininogen, factor XII, thrombomodulin and tissue plasminogen activator. A majority of thesefactors participate in the initial phase of coagulation cascade or in additional mechanisms ofchecking on the cascade. It is possible that antibodies against these proteins can affect coagulationbalance. The syndrome represented by positive LA and aCL antibodies has been called antiphospholipidsyndrome. The basic concept of this syndrome is characterized by thrombophilic syndrome.The main spectrum of clinical manifestations of APS includes arterial and venous thromboses,spontaneous fetal losses and thrombocytopenia.

Key words:
lupus anticoagulant, antiphospholipid syndrome

Full text is not available online.
If interested in a scan of this journal, contact NTO ČLS JEP.

Dermatology & STDs Paediatric rheumatology Rheumatology
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account